http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 19:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+09++Filed+by%3A+TANG+KEVIN/26763443.html si-local-file:///var/storage/secattach/20260713/26763443.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+09++Filed+by%3A+TANG+KEVIN/26763443.html Mon, 13 Jul 2026 19:06:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+09++Filed+by%3A+TANG+KEVIN/26763443.html si-local-file:///var/storage/secattach/20260713/26763443.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+09++Filed+by%3A+TANG+KEVIN/26763443.html Mon, 13 Jul 2026 19:06:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+06++Filed+by%3A+TANG+KEVIN/26748726.html si-local-file:///var/storage/secattach/20260708/26748726.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+06++Filed+by%3A+TANG+KEVIN/26748726.html Wed, 08 Jul 2026 20:06:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+06++Filed+by%3A+TANG+KEVIN/26748726.html si-local-file:///var/storage/secattach/20260708/26748726.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+06++Filed+by%3A+TANG+KEVIN/26748726.html Wed, 08 Jul 2026 20:06:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+GILLIS+STEVEN/26736794.html si-local-file:///var/storage/secattach/20260706/26736794.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+GILLIS+STEVEN/26736794.html Mon, 06 Jul 2026 17:45:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+GILLIS+STEVEN/26736794.html si-local-file:///var/storage/secattach/20260706/26736794.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+GILLIS+STEVEN/26736794.html Mon, 06 Jul 2026 17:45:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+ARCH+Venture+Partners+X+Overage%2C+L.P./26736786.html si-local-file:///var/storage/secattach/20260706/26736786.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+ARCH+Venture+Partners+X+Overage%2C+L.P./26736786.html Mon, 06 Jul 2026 17:43:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+ARCH+Venture+Partners+X+Overage%2C+L.P./26736786.html si-local-file:///var/storage/secattach/20260706/26736786.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jul+01++Filed+by%3A+ARCH+Venture+Partners+X+Overage%2C+L.P./26736786.html Mon, 06 Jul 2026 17:43:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+30++Filed+by%3A+TANG+KEVIN/26730121.html si-local-file:///var/storage/secattach/20260702/26730121.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+30++Filed+by%3A+TANG+KEVIN/26730121.html Thu, 02 Jul 2026 19:46:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+30++Filed+by%3A+TANG+KEVIN/26730121.html si-local-file:///var/storage/secattach/20260702/26730121.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+30++Filed+by%3A+TANG+KEVIN/26730121.html Thu, 02 Jul 2026 19:46:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Boundless+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26708053.html si-local-file:///var/storage/secattach/20260629/26708053.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Boundless+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26708053.html Mon, 29 Jun 2026 19:58:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Boundless+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26708053.html si-local-file:///var/storage/secattach/20260629/26708053.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++Boundless+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+TANG+CAPITAL+MANAGEMENT+LLC/26708053.html Mon, 29 Jun 2026 19:58:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708051.html si-local-file:///var/storage/secattach/20260629/26708051.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708051.html Mon, 29 Jun 2026 19:56:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708051.html si-local-file:///var/storage/secattach/20260629/26708051.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708051.html Mon, 29 Jun 2026 19:56:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708046.html si-local-file:///var/storage/secattach/20260629/26708046.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708046.html Mon, 29 Jun 2026 19:52:00 -0400 BOLD O.15817313 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708046.html si-local-file:///var/storage/secattach/20260629/26708046.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Boundless+Bio%2C+Inc.+++++++For%3A+Jun+25++Filed+by%3A+TANG+KEVIN/26708046.html Mon, 29 Jun 2026 19:52:00 -0400 BOLD O.15817313 http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Press+Releases/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html <p>DENVER, June 23, 2026 (GLOBE NEWSWIRE) -- (<a href="https://www.globenewswire.com/Tracker?data=Nt8bqOjTEXQrkGToUrhKw_CoR9RfATlSj_94iGSUibNse2x-7UHOxXYQvIumJ2zXgdEfi4HUfYIfNq8hYgiRSXS1U7u3bRsZRj6bWDKatfM=" rel="nofollow" target="_blank">247marketnews.com</a>) -- Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points.</p> <p><strong>NeOnc Technologies Approaches Major Clinical Catalyst</strong></p> <p><strong>NeOnc Technologies (NASDAQ: NTHI)</strong> has emerged as a company attracting attention within the neuro-oncology sector after announcing that the Department of Health–Abu Dhabi granted Investigational New Drug authorization for its NEO100 program. The approval covers multiple protocols spanning adult Phase 1 through Phase http://www.streetinsider.com/Globe+Newswire/These+Emerging+Companies+Are+Racing+Toward+Major+Catalysts/26677919.html Tue, 23 Jun 2026 11:11:05 -0400 BLZE BOLD HSCS NTHI http://www.streetinsider.com/SEC+Filings/Form++425++++++++Boundless+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+Boundless+Bio%2C+Inc./26676529.html si-local-file:///var/storage/secattach/20260623/26676529.html http://www.streetinsider.com/SEC+Filings/Form++425++++++++Boundless+Bio%2C+Inc.++++++++++++++++++++Filed+by%3A+Boundless+Bio%2C+Inc./26676529.html Tue, 23 Jun 2026 08:35:00 -0400 BOLD O.15817313